Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Sygnis Pharma
Sygnis Pharma
Activities:
Research & Development
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Analysis
SYGNIS AG announces the launch of TrueHelix
The first tool on the TrueHelix platform addresses sample contamination, a key pitfall in NGS workflows
Ingredients
SYGNIS AG reinforces its proteomics portfolio with two patents granted in Europe and China
Granted patents confirm innovation and novelty of proteomics product range
Research & Development
Sygnis strengthens management team with appointment of Heikki Lanckriet
He joins the DNA amplification and sequencing firm as joint CEO and Chief Scientific Officer
Subscribe now